Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Massimo Radin, Irene Cecchi, Karen Schreiber, Simone Baldovino, Daniela Rossi, Elisa Menegatti, Dario Roccatello & Savino Sciascia. (2017) Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. Expert Opinion on Orphan Drugs 5:1, pages 55-69.
Read now
Read now
Huza Zhang, William Chambers, Savino Sciascia & Maria J. Cuadrado. (2016) Emerging therapies in systemic lupus erythematous: from clinical trial to the real life. Expert Review of Clinical Pharmacology 9:5, pages 681-694.
Read now
Read now
Chi Chiu Mok. (2014) Emerging biological therapies for systemic lupus erythematosus. Expert Opinion on Emerging Drugs 19:2, pages 303-322.
Read now
Read now
Radu Tanasescu, Nikos Evangelou & Cris S Constantinescu. (2013) Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment 9, pages 539-553.
Read now
Read now
Jan Thöne & Gisa Ellrichmann. (2013) Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug, Healthcare and Patient Safety 5, pages 37-47.
Read now
Read now
Jan Thöne & Ralf Gold. (2013) Review of laquinimod and its therapeutic potential in multiple sclerosis. Expert Opinion on Pharmacotherapy 14:18, pages 2545-2552.
Read now
Read now
Rina Aharoni. (2013) New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis. Expert Review of Clinical Immunology 9:5, pages 423-440.
Read now
Read now
Articles from other publishers (19)
Chao Ma, Mohammed S. Taghour, Amany Belal, Ahmed B. M. Mehany, Naglaa Mostafa, Ahmed Nabeeh, Ibrahim H. Eissa & Ahmed A. Al-Karmalawy. (2021) Design and Synthesis of New Quinoxaline Derivatives as Potential Histone Deacetylase Inhibitors Targeting Hepatocellular Carcinoma: In Silico, In Vitro, and SAR Studies. Frontiers in Chemistry 9.
Crossref
Crossref
Anna Elgart, David J. Greenblatt, Pippa S. Loupe, Arik A. Zur, Sivan Weiss, Dorit Mimrod & Ofer Spiegelstein. (2020) The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator. Clinical Pharmacology in Drug Development 9:8, pages 1015-1024.
Crossref
Crossref
Anna Elgart, Arik A. Zur, Dorit Mimrod, Vered Dror, Oren Bar-Ilan, Tjeerd Korver & Ofer Spiegelstein. (2018) The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women. European Journal of Clinical Pharmacology 75:1, pages 41-49.
Crossref
Crossref
Ofer Spiegelstein, Dorit Mimrod, Laura Rabinovich, Eli Eyal, Craig Sprenger, Anna Elgart, Emil Samara & Joel Morganroth. (2019) A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease. Clinical Pharmacology in Drug Development 8:1, pages 49-59.
Crossref
Crossref
Savino Sciascia, Massimo Radin, Dario Roccatello, Giovanni Sanna & Maria Laura Bertolaccini. (2018) Recent advances in the management of systemic lupus erythematosus. F1000Research 7, pages 970.
Crossref
Crossref
R. Marignier, A. Ruiz, S. Cavagna, A. Nicole, C. Watrin, M. Touret, S. Parrot, G. Malleret, C. Peyron, C. Benetollo, N. Auvergnon, S. Vukusic & P. Giraudon. (2016) Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. Journal of Neuroinflammation 13:1.
Crossref
Crossref
Michel Varrin-DoyerKara L. PekarekCollin M. SpencerClaude C.A. BernardRaymond A. SobelBruce A.C. CreeUlf Schulze-TopphoffScott S. Zamvil. (2016) Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. Neurology Neuroimmunology & Neuroinflammation 3:5.
Crossref
Crossref
Dagmar E. Ehrnhoefer, Nicholas S. Caron, Yu Deng, Xiaofan Qiu, Michelle Tsang & Michael R. Hayden. (2016) Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Experimental Neurology 283, pages 121-128.
Crossref
Crossref
C. C. Mok. (2016) Towards new avenues in the management of lupus glomerulonephritis. Nature Reviews Rheumatology 12:4, pages 221-234.
Crossref
Crossref
Benedikt Kretzschmar, Hannah Pellkofer & Martin S. Weber. (2016) The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis. Current Neurology and Neuroscience Reports 16:4.
Crossref
Crossref
Savino Sciascia, Eva Talavera-Garcia, Dario Roccatello, Simone Baldovino, Elisa Mengatti & Maria Jose Cuadrado. (2015) Upcoming biological therapies in systemic lupus erythematosus. International Immunopharmacology 27:2, pages 189-193.
Crossref
Crossref
Michel Varrin-Doyer, Scott S. Zamvil & Ulf Schulze-Topphoff. (2014) Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Experimental Neurology 262, pages 66-71.
Crossref
Crossref
Alireza Minagar. (2014) Multiple Sclerosis: An Overview of Clinical Features, Pathophysiology, Neuroimaging, and Treatment Options. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 6:4, pages 1-117.
Crossref
Crossref
Alan M. Palmer. (2014) New and emerging immune-targeted drugs for the treatment of multiple sclerosis. British Journal of Clinical Pharmacology 78:1, pages 33-43.
Crossref
Crossref
Renaud A. Du Pasquier, Daniel D. Pinschewer & Doron Merkler. (2014) Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis. CNS Drugs 28:6, pages 535-558.
Crossref
Crossref
Manoj Kumar Mishra, Janet Wang, Michael B. Keough, Yan Fan, Claudia Silva, Scott Sloka, Liat Hayardeny, Wolfgang Brück & V. Wee Yong. (2014) Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Annals of Clinical and Translational Neurology 1:6, pages 409-422.
Crossref
Crossref
Wolfgang Brück & Timothy Vollmer. (2013) Oral laquinimod for MS—bringing the brain into focus. Nature Reviews Neurology 9:12, pages 664-665.
Crossref
Crossref
Alireza Minagar. (2013) Current and Future Therapies for Multiple Sclerosis. Scientifica 2013, pages 1-11.
Crossref
Crossref
Wolfgang Brück, Ramona Pförtner, Trinh Pham, Jingya Zhang, Liat Hayardeny, Victor Piryatinsky, Uwe-Karsten Hanisch, Tommy Regen, Denise van Rossum, Lars Brakelmann, Karin Hagemeier, Tanja Kuhlmann, Christine Stadelmann, Gareth R. John, Nadine Kramann & Christiane Wegner. (2012) Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathologica 124:3, pages 411-424.
Crossref
Crossref